CN105595341B - A kind of lycopene composition with anti-oxidant alleviation visual fatigue - Google Patents
A kind of lycopene composition with anti-oxidant alleviation visual fatigue Download PDFInfo
- Publication number
- CN105595341B CN105595341B CN201610060020.7A CN201610060020A CN105595341B CN 105595341 B CN105595341 B CN 105595341B CN 201610060020 A CN201610060020 A CN 201610060020A CN 105595341 B CN105595341 B CN 105595341B
- Authority
- CN
- China
- Prior art keywords
- lycopene
- parts
- oxidant
- visual fatigue
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 title claims abstract description 78
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 title claims abstract description 75
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 title claims abstract description 75
- 235000012661 lycopene Nutrition 0.000 title claims abstract description 75
- 239000001751 lycopene Substances 0.000 title claims abstract description 75
- 229960004999 lycopene Drugs 0.000 title claims abstract description 75
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 title claims abstract description 75
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 21
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 19
- 235000006708 antioxidants Nutrition 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 44
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 34
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims abstract description 26
- 235000014837 Malpighia glabra Nutrition 0.000 claims abstract description 26
- 239000012141 concentrate Substances 0.000 claims abstract description 26
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 21
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 16
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 16
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 16
- 229960004853 betadex Drugs 0.000 claims abstract description 16
- 240000003394 Malpighia glabra Species 0.000 claims description 24
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 235000012680 lutein Nutrition 0.000 claims description 7
- 239000001656 lutein Substances 0.000 claims description 7
- 229960005375 lutein Drugs 0.000 claims description 7
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 7
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 229940083466 soybean lecithin Drugs 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- CODAYFPFZXWNLD-UHFFFAOYSA-N 2-hydroxypropanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)C(C)O CODAYFPFZXWNLD-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 229940099112 cornstarch Drugs 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 241000227653 Lycopersicon Species 0.000 claims 6
- 230000000694 effects Effects 0.000 abstract description 13
- 238000005516 engineering process Methods 0.000 abstract description 5
- 241001640002 Malpighia emarginata Species 0.000 abstract 2
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 17
- 239000000463 material Substances 0.000 description 13
- 240000003768 Solanum lycopersicum Species 0.000 description 12
- 210000001508 eye Anatomy 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 206010034960 Photophobia Diseases 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 235000021466 carotenoid Nutrition 0.000 description 4
- 239000011162 core material Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- -1 isoprenoid compound Chemical class 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 244000298715 Actinidia chinensis Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000779599 Malpighia Species 0.000 description 1
- 244000007729 Malpighia coccigera Species 0.000 description 1
- 235000014791 Malpighia coccigera Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007697 cis-trans-isomerization reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000004373 eye development Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a kind of lycopene composition with anti-oxidant alleviation visual fatigue, the composition is made of the component of following parts by weight: 10-50 parts of lycopene oil, 10-50 parts of lutein ester, 10-50 parts of acerola concentrate powder.Lycopene in the present invention, lutein ester, acerola concentrate three synergistic effect play preferably anti-oxidant, alleviation visual fatigue health-care effect.Simultaneously invention additionally discloses a kind of technology of beta-cyclodextrin embedding lycopene oil, lycopene oil instability problem is effectively solved, the quality of product of the present invention is improved.
Description
Technical field
The invention belongs to field of health care food, and in particular to a kind of with tomato red plain piece that is anti-oxidant, alleviating visual fatigue
And preparation method thereof.
Background technique
Lycopene is also known as ψ-carrotene, belongs to isoprenoid compound, is one kind of carotenoid.Due to most
Early separate from tomato is made, therefore claims lycopene.Lycopene passes through physics and chemical mode quenching singlet oxygen or capture
Peroxylradicals.Singlet oxygen is that have very strongly active oxygen radical, has cytotoxic effect, with cell membrane, mitochondria
Equal positions are most sensitive to its, can have an effect with large biological molecules a variety of in cell, by causing cell membrane in conjunction with molecule
The damage of system；Lycopene can receive the energy of different excited electronic states, absorb luminous energy and pass through singlet-singlet
Energy transfer process makes the energy transfer of singlet oxygen to lycopene, generates ground state oxygen molecule and triplet lycopene point
Son, triplet lycopene are regenerated by a series of optically-actives with solvent and dynamic respons, and in the process by energy
It distributes；The number of conjugated double bond contained in the quenching ability of carotenoid and its molecule has close relationship, tomato red
There are 11 conjugated double bonds in plain molecule, a lycopene molecule can remove thousands of singlet oxygens, quenching singlet oxygen
Rate constant it is 2 times high compared with beta carotene.It is anti-that nineteen ninety Paolo etc. reports more than 30 biology such as carotenoid and tocopherol
The effect of oxidant quenching singlet oxygen, lycopene are that quenching singlet oxygen is strongest.Meanwhile lycopene is largely present in
Internal various mucous membrane tissues, the various various discomforts caused because internal mucous membrane tissue destroys can be improved by taking for a long time.As done
Cough, eyes are dry and astringent, canker sore, protection gastrointestinal tract mucosa tissue etc..
Lutein ester is a kind of important carotenoid aliphatic ester, and stability is better than lutein, only high temperature,
Lutein ester is destroyed under the factors such as strong acid, iron ion and oxygen larger.Lutein ester is decomposed into free state leaf after absorption of human body
Flavine is lost the basic function of lutein with crystal lutein supplement human body.And the importance of lutein is in the nutrition in the whole world
Educational circles is all affirmed why the macula area of human eye is yellow color, exactly because it is filled with lutein and its homologous series
Object.Lutein filter blue light and oxidation resistant effect are to aid in the critical nutrients element of eye development.Therefore, someone is also leaf
Flavine is compared to " stealthy sunglasses ".
Acerola concentrate is the fruit of Malpighiaceae Malpighia concave edge Malpighia coccigera, and acerola concentrate is in the plant planted at present
Vitamin C content third is high, and Victoria C content is only second to Ka Kaduli and Ka Mu fruit, is lemon up to 1677 milligrams in every 100 grams of fruits
31 times of lemon, 18 times of Kiwi berry, are also considered as 7 times of the high guava of vitamin C by 27 times of strawberry, be name it is secondary its
Real one of " king of natural vitamin C ", while also containing elements such as dimension A, dimension B1, dimension B2, iron, calcium, vitamin C is to maintain people
The integral important composition of body life, it anti-can catch a cold, anti-scurvy, improve human body resistivity, to beauty and cancer
Disease has certain effect.It is widely used in terms of health care, beverage, beauty.
Embedding techniques (microencapsulation) are also known as microcapsules technology, refer to and utilize natural or synthetic macromolecule
Material (is commonly referred to as wall material), and solid, liquid or gas material (being commonly referred to as heartwood) are formed by a kind of with semi-transparent through packing
Property or sealing cyst membrane microencapsulation technology, be widely applied in the fields such as pharmacy, food, fragrance, agricultural chemicals.β-ring paste
Smart (β-Cyclodextrin, β-CD) is the wall material of most study, it by 7 glucose molecules with α-Isosorbide-5-Nitrae glucosides key connection and
At main body conformation is that a centre has cavity, the not closed cylinder in both ends, and significant structure feature is that there are a three-dimensional cylinders
Shape chirality hydrophobic cavity, special nonpolar hydrophobic environments enable β-CD with power the effects of Van der Waals force, hydrophobic and hydrogen bond, with one
The hydrophobic group effect of a little polarity, size, the molecule that shape and property match or certain molecules, it is complete in its space structure
Portion or part are packed in another molecule and form stable supermolecule inclusion compound, claim beta-CD inclusion or β-CD molecular microcapsule.
β-CD in inclusion compound outer layer is known as host molecule, is known as the enclosed molecule (heart by the small-molecule substance included within host molecule
Material).There are the center an of relative hydrophobic and the surface of a relative hydropathic due to beta-cyclodextrin, during enclosed molecule substance is embedded in
Between, it not only can be uniformly dispersed in use, but also enclosed molecule substance is played a certain protective role.
There are 11 conjugated double bonds and 2 unconjugated double bonds in lycopene molecule, so that the stability of lycopene compares
Cis-trans isomerization and oxidative degradation can occur under certain condition for difference, cause lycopene formulations unstable, so on the market kind
Lycopene dosage form is generally soft capsule, but soft capsule technique is with high requirements and high cost.
Summary of the invention
The purpose of the present invention is overcoming above-mentioned shortcoming, providing one kind being capable of safely, effectively anti-oxidant, alleviation visual fatigue
Lycopene composition.
It is a further object of the present invention to provide the preparation methods of the lycopene composition tablet.
It is a still further object of the present invention to provide the tablets can application that is effectively anti-oxidant, alleviating visual fatigue.
The purpose of the present invention is what is be accomplished by the following way:
A kind of lycopene composition with anti-oxidant alleviation visual fatigue, it is made of the component of following parts by weight: kind
10-50 parts of Lycopene oil, 10-50 parts of lutein ester, 10-50 parts of acerola concentrate powder.
It is above-mentioned to be preferably made of the component of following parts by weight with lycopene composition that is anti-oxidant, alleviating visual fatigue:
45-50 parts of lycopene oil, 10-20 parts of lutein ester, 10-20 parts of acerola concentrate powder.
Preparation can be made in the composition with pharmaceutically acceptable auxiliary material, and preferred formulation is tablet, capsule, granule, ball
Agent, oral solution.
Above-mentioned tablet is mainly made of the component of following parts by weight: 10-50 parts of lycopene oil, 10-50 parts of lutein ester,
10-50 parts of acerola concentrate powder, 10-100 parts of beta-cyclodextrin.
Preferred tablet is mainly made of the component of following parts by weight: 45-50 parts of lycopene oil, 10-20 parts of lutein ester,
10-20 parts of acerola concentrate powder, 50-90 parts of beta-cyclodextrin.
It further include emulsifier and food grade accessories in the tablet.Food grade accessories may be used as the filler for being pressed into tablet,
Lubricant, bonding agent etc..
The emulsifier is preferred are as follows: Tween-80, monoglyceride, and three polyglycerol esters, soybean lecithin, lauric monoglyceride,
At least one of stearoyl lactate or several mixing, emulsifier are the 0-1% of lycopene oil weight；Food grade accessories
Are as follows: cornstarch, D-sorbite, maltodextrin, microcrystalline cellulose, lactose, magnesium stearate, at least one of antierythrite or several
Kind mixing, dosage are the 1%-10% of the weight of lutein ester, acerola concentrate powder and lycopene powder total weight.
It is of the present invention with it is anti-oxidant, alleviate visual fatigue tomato red plain piece preparation method the following steps are included:
A. beta-cyclodextrin is taken to be dissolved in 50-80 DEG C of distilled water as wall material, constant temperature 10-50min, be added emulsifier and
As the lycopene oil of core material, homogeneous is spray-dried to obtain lycopene powder；
B. lutein ester, acerola concentrate powder and lycopene powder mixing are taken, then is mixed with food grade accessories, tabletting to obtain the final product.
Processing condition in the step a: 20-60 DEG C of temperature, pressure 10-40MPa.Spray drying condition: injector temperature
100-200 DEG C, 50-100 DEG C of outlet temperature, flow velocity 500-1500ml/h.
Raw material used in the present invention: lycopene oil (Shaanxi Sen Fu natural product Co., Ltd, lycopene >=
10%), lutein ester (the Xi'an biotech inc Yue Da, lutein ester >=90%), acerola concentrate powder (are thought in Hainan
Tan De Biotechnology Co., Ltd, VC content >=10%).
Beneficial effects of the present invention compared with the prior art:
1, three kinds of lutein ester, acerola concentrate powder and lycopene substance connected applications are played synergy by the present invention
Effect, proves by concrete function evaluation experimental, and the present invention plays the role of preferably anti-oxidant, alleviation visual fatigue.
2, lycopene oil is normally only used for soft capsule dosage form, and due to the special nature of raw material, soft capsule dosage form has been difficult to
At the combination of many kinds of substance of the present invention, the present invention combines specific auxiliary material, embeds lycopene oil using special beta-cyclodextrin
Technology, effectively solve lycopene oil instability problem while, also enable to have with lutein ester and acerola concentrate powder
Effect combines, and the tablet being not only prepared into meets formulation requirements, but also bioavilability can also significantly improve.
3, Tablets overcome Lycopene Tablets by UV Spectrophotometry wild effect, and low in cost, convenient to take.
It is tired below by way of further illustrating that there is tomato red plain piece of the present invention anti-oxidant, alleviation to regard to specific pharmacodynamic test example
The effect of labor.
One, alleviate visual fatigue functional evaluation experiment
1. material and method
Sample and placebo: tomato red plain piece 1 of the invention, No. 2, the two base in packaging, appearance, color and mouthfeel
This is consistent, and tomato red plain piece 1 is tomato red plain piece (being prepared according to 1 method of embodiment) of the invention, another is peace
Console agent.Population takes one time a day, and 1 tablet once.
2. subject selects
Experimenter's mass selection is selected: eye, the fatigable adult of eyesight are used in selection for a long time.All richnesses meet above-mentioned condition and voluntary participation
And guarantee that cooperation person can be included in test.
3. test method
Using itself, two kinds of control designs will meet the standard of being included in and guarantee to match according to random, double blind requirement between group
Close test volunteer, according to symptom, eye test situation, at the same consider the factors such as age, gender be divided into tested group and
Control group.Tested group and control group take sample or placebo by recommended dose, and continuous 45 days.Do not change during test original
Eating habit, normal diet.
4, efficiency index
Symptom Observation: inquiry visual fatigue situation in detail, observation ophthalmodynia, the symptoms such as eye is swollen, photophobia, eye are dry and astringent, by mild symptoms
Multiple integral (severe 3 is divided, and middle disease 2 is divided, and mild 1 is divided) counts integrated value before and after test-meal, and improves (any symptom with regard to its symptom
Improving 1 point, the above are improve) situation, observe the symptoms improvement rate.
It is to improve that the dry and astringent any symptom of photophobia, blurred vision, eye, which improves 1 point and 1 point or more, 5 kinds of any improvement of symptom
Other symptoms improve without i.e. judgement symptom is deteriorated.
5. result
5.1, ordinary circumstance: initial trial trial population group 54, control group 54, test-meal group: male/female 19/53, year
Age is 51.61 ± 11.39 years old；Control group: male/female 20/34, age are 51.15 ± 11.57 years old.Subject's essence during test-meal
Mind, sleep, diet, stool and urine are normal.
5.2, functional observation
See Tables 1 and 2, test-meal group ophthalmodynia, eye be swollen after test-meal, photophobia, blurred vision, eye are dry and astringent etc., and clinical symptoms have obviously
Improve, obvious reduction before symptom integral and test-meal, difference has conspicuousness (P < 0.05), compared with the control group, difference
There is conspicuousness (P < 0.05).
Symptom integral statistics before and after the tablet test-meal of the invention of table 1
Symptom improves situation before and after the tablet test-meal of the invention of table 2
The results showed that tomato red plain piece of the invention is to ophthalmodynia, the clinics such as eye is swollen, photophobia, blurred vision, eye are dry and astringent
Symptom has improvement, after test before test-meal group symptom integral and test-meal and control group comparing difference has conspicuousness (P < 0.05)；With it is right
There is conspicuousness (P < 0.05) according to a group comparing difference, it was demonstrated that Tablets, which have, alleviates visual fatigue effect.
Two, anti-oxidation function evaluation experimental
1, material and method
1.1 sample
Tomato red plain piece (being prepared according to 1 method of embodiment) of the invention, no lycopene negative control sample, tomato
Red pigment powder (is prepared) according to 1 method of embodiment.
1.2 animal
Select the 12 monthly age male mices bred by Jiangning county Qinglongshan animal reproduction field.
The selection of 1.3 dosage
Tablet dosage of the invention is adult (weight 60kg) daily 4, and every 3g is equivalent to 0.2g/ days/kg.Administration
Orally administration, rat oral gavage volume are 0.01g/100g mouse weight to group rat 2 times a day, and sample is using water-soluble rear stomach-filling.3 are set simultaneously
Group control group, blank group replace Tablets with water, and daily stomach-filling is identical as embodiment sample group dosage.Lycopene powder group
Daily stomach-filling is identical as embodiment sample group dosage, and (the preparation method is the same as that of Example 1, only few kind of component for no lycopene group
Lycopene oil) daily stomach-filling is identical as embodiment sample group dosage.
2, experimental method
According to the dose design stomach-filling in 1.3 give different groups by test solution, daily stomach-filling is primary, and stomach-filling volume is
0.1ml/10gbw, continuous 30 days.31st day, the content of blood sampling measurement MDA on Mouse Tail-tip, and eyeball blood sampling is plucked, centrifugation,
Serum is taken, serum superoxide dismutases (SOD) vigor and glutathione peroxidase (GSH-PX) vigor is measured, as a result examines
Proved recipe method uses t between group to examine.
3, result
3 separate groups of mice SOD vigor of table and GSH-PX vigor
| Group | Number of cases | SOD(U/ml) | GSH-PX(U/L) |
| Blank group | 12 | 154.31±27.11 | 537.1±71.2 |
| Example 1 group | 12 | 271.23±37.72 | 731.3±67.7 |
| Lycopene powder group | 12 | 178.92±29.13 | 610.3±59.3 |
| Without lycopene group | 12 | 163.21±31.21 | 598.4±61.2 |
3 are shown in Table as it can be seen that embodiment group SOD in Mice vigor and GSH-PX vigor illustrate tablet of the invention higher than other groups
With oxidation resistant effect, at the same 1 tablet antioxidant effect of the embodiment of the present invention and be used alone lycopene powder group and without kind
Lycopene group more has significant difference.
Safety testing is carried out using 1 tablet of embodiment
Rat 30d feeding trial: rat gives standard feed, raising in (20 ± 3) DEG C, humidity (40 ± 5) %, artificial shine
Under bright 10h environment, timing ventilation.After adapting to 5d, it is randomly divided into 4 groups, every group 20, half male and half female.If basic, normal, high 3 dosage
Group, dosage are respectively 1.0,2.5,5.0g/kg, separately set negative control group, using daily gastric infusion, mix medical fluid before being administered,
Stomach-filling amount is 1.0ml/kg weight.Rat clinical manifestation is observed and recorded daily, and every 5d claims a weight and food to take the photograph people's amount, meter
Calculate efficiency of feed utilization.30d upon administration, every group takes 10 animals respectively, carries out following check: (1) hematological examination: plucking eye
Ball blood sampling, meets 1mL in heparin tube, surveys red blood cell (RBC), hemoglobin (HB), hematocrit (HCT), mean corpuscular
Volume (MCV), mean corpuscular hemoglobin (MCH), leucocyte (WBC), lymphocyte (LYM), monocyte (MO), in
Property granulocyte (GR) and blood platelet (PLT) content.
Give lycopene tablet rat blood inspection result
Rat 30d feeding trial the result shows that, senior middle school's low dose group hematological indices and control group are without significant difference, it was demonstrated that
Tomato red plain piece edible safety of the present invention.
Specific embodiment
Form by the following examples is described in further detail above content of the invention again, but should not be by this
The range for being interpreted as the above-mentioned theme of the present invention is only limitted to example below, and all technologies realized based on above content of the present invention are equal
Belong to the scope of the present invention.
Embodiment 1:
Main formula:
Lycopene oil 500g, lutein ester 100g, acerola concentrate powder 100g, beta-cyclodextrin 500g.
Preparation method:
A. beta-cyclodextrin is taken to be dissolved in 50 DEG C of distilled water, 1% emulsification of lycopene oil weight is added in constant temperature 30min
Agent monoglyceride and lycopene oil (core material and wall material ratio be 1:1), homogeneous, processing condition temperature 50 C, pressure 30MPa, spray
Mist it is dry lycopene powder, spray drying condition: 150 DEG C of injector temperature, 75 DEG C of outlet temperature, flow velocity 1500ml/h.
B. take lutein ester, acerola concentrate powder and lycopene powder mixing, then with maltodextrin and microcrystalline cellulose (malt
Dextrin and microcrystalline cellulose weight ratio 1:1, dosage are the 1% of lutein ester, acerola concentrate powder and lycopene powder total weight),
It mixes, to obtain the final product, slice weight 0.4g amounts to 3000 for tabletting.
| 1 tablet index of embodiment | |
| Weight differential | - 0.3-0.9% |
| Disintegration time limited | 17min |
| Microbial limit | It is qualified |
Embodiment 2:
Main formula:
Lycopene oil 450g, lutein ester 100g, acerola concentrate powder 100g, beta-cyclodextrin 900g.
Preparation method:
A. beta-cyclodextrin is taken to be dissolved in 80 DEG C of distilled water, 0.5% cream of lycopene oil weight is added in constant temperature 30min
Agent soybean lecithin and lycopene oil (core material and wall material ratio be 1:2), homogeneous, 30 DEG C of processing condition temperature, pressure
40MPa is spray-dried to obtain lycopene powder, spray drying condition: 170 DEG C of injector temperature, 85 DEG C of outlet temperature, and flow velocity
1000ml/h.；
B. take lutein ester, acerola concentrate powder and lycopene powder mixing, then with food grade accessories microcrystalline cellulose (dosage
Be the 3% of lutein ester, acerola concentrate powder and lycopene powder total weight) mix, tabletting to obtain the final product, slice weight 0.4g.
| 2 tablet index of embodiment | |
| Weight differential | - 0.3-0.9% |
| Disintegration time limited | 17min |
| Microbial limit | It is qualified |
Embodiment 3:
Main formula:
Lycopene oil 180g, lutein ester 180g, acerola concentrate powder 180g, beta-cyclodextrin 900g.
Preparation method:
A. beta-cyclodextrin is taken to be dissolved in 80 DEG C of distilled water, 0.5% cream of lycopene oil weight is added in constant temperature 30min
Agent soybean lecithin and lycopene oil (core material and wall material ratio be 1:5), homogeneous, 30 DEG C of processing condition temperature, pressure
40MPa is spray-dried to obtain lycopene powder, spray drying condition: 170 DEG C of injector temperature, 85 DEG C of outlet temperature, and flow velocity
1000ml/h.；
B. take lutein ester, acerola concentrate powder and lycopene powder mixing, then with food grade accessories microcrystalline cellulose (dosage
Be the 3% of lutein ester, acerola concentrate powder and lycopene powder total weight) mix, tabletting to obtain the final product, slice weight 0.4g.
| 3 tablet index of embodiment | |
| Weight differential | - 0.3-0.9% |
| Disintegration time limited | 17min |
| Microbial limit | It is qualified |
Claims (6)
1. a kind of with tomato red plain piece that is anti-oxidant, alleviating visual fatigue, it is characterised in that kind of the anti-oxidant alleviation visual fatigue
Lycopene piece is prepared by the following method to obtain: it takes in 10-100 parts of the beta-cyclodextrin distilled water for being dissolved in 50-80 DEG C, it is permanent
Warm 10-50min is added lycopene oil 10-50 parts and emulsifier, homogeneous, is spray-dried to obtain lycopene powder；Take lutein ester
10-50 parts, 10-50 parts of acerola concentrate powder and lycopene powder mixing, then mixed with food grade accessories, tabletting to obtain the final product.
2. according to claim 1 with tomato red plain piece that is anti-oxidant, alleviating visual fatigue, it is characterised in that the piece
Lycopene oil 45-50 parts when preparation, 10-20 parts of lutein ester, 10-20 parts of acerola concentrate powder, 50-90 parts of beta-cyclodextrin.
3. according to claim 1 with tomato red plain piece that is anti-oxidant, alleviating visual fatigue, it is characterised in that the cream
Agent are as follows: Tween-80, monoglyceride, three polyglycerol esters, soybean lecithin, lauric monoglyceride, at least one in stearoyl lactate
Kind or several mixing, emulsifier are the 0-1% of lycopene oil weight；Food grade accessories are as follows: cornstarch, D-sorbite,
Maltodextrin, microcrystalline cellulose, lactose, magnesium stearate, at least one of antierythrite or several mixing, dosage are lutein
The 1%-10% of ester, acerola concentrate powder and lycopene powder total weight.
4. the system with tomato red plain piece that is anti-oxidant, alleviating visual fatigue described in claim 1-3 any one claim
Preparation Method, it is characterised in that method includes the following steps:
A. beta-cyclodextrin is taken to be dissolved in 50-80 DEG C of distilled water, emulsifier and lycopene oil is added in constant temperature 10-50min,
Homogeneous is spray-dried to obtain lycopene powder；
B. lutein ester, acerola concentrate powder and lycopene powder mixing are taken, then is mixed with food grade accessories, tabletting to obtain the final product.
5. the preparation method according to claim 4 with tomato red plain piece that is anti-oxidant, alleviating visual fatigue, feature exist
The processing condition in the step a: 20-60 DEG C of temperature, pressure 10-40MPa.
6. the preparation method according to claim 4 with tomato red plain piece that is anti-oxidant, alleviating visual fatigue, feature exist
The spray drying condition in the step a: 100-200 DEG C of injector temperature, 50-100 DEG C of outlet temperature, flow velocity 500-
1500ml/h。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610060020.7A CN105595341B (en) | 2016-01-28 | 2016-01-28 | A kind of lycopene composition with anti-oxidant alleviation visual fatigue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610060020.7A CN105595341B (en) | 2016-01-28 | 2016-01-28 | A kind of lycopene composition with anti-oxidant alleviation visual fatigue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105595341A CN105595341A (en) | 2016-05-25 |
| CN105595341B true CN105595341B (en) | 2018-12-04 |
Family
ID=55976144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610060020.7A Active CN105595341B (en) | 2016-01-28 | 2016-01-28 | A kind of lycopene composition with anti-oxidant alleviation visual fatigue |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105595341B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106723012A (en) * | 2016-11-19 | 2017-05-31 | 乌鲁木齐市疆域绿色营养源研究院（有限公司） | A kind of lycopene powder and compound fruit and vegetable piece |
| CN106579111A (en) * | 2016-11-29 | 2017-04-26 | 广州汇圣森丰农业科技发展有限公司 | Black tomato chewable tablet with anti-oxidation effect |
| CN109419775B (en) * | 2017-08-25 | 2021-02-09 | 南京生矶坊生物工程有限公司 | Water-soluble lycopene and preparation method and application thereof |
| WO2019109346A1 (en) * | 2017-12-08 | 2019-06-13 | 晨光生物科技集团股份有限公司 | Lycopene micro-capsule powder and preparation method therefor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813763A (en) * | 2005-02-04 | 2006-08-09 | 南京师范大学 | Lycopene/beta-cyclodextrin supermolecular composition and its preparation |
| US20100004330A1 (en) * | 2008-07-02 | 2010-01-07 | Li Lin Huang | Anti-oxidative content material used in drink and food manufacturing method |
| CN103735733A (en) * | 2013-12-30 | 2014-04-23 | 杭州海杭生物医药科技有限公司 | Compound preparation containing lutein ester and preparation method thereof |
-
2016
- 2016-01-28 CN CN201610060020.7A patent/CN105595341B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1813763A (en) * | 2005-02-04 | 2006-08-09 | 南京师范大学 | Lycopene/beta-cyclodextrin supermolecular composition and its preparation |
| US20100004330A1 (en) * | 2008-07-02 | 2010-01-07 | Li Lin Huang | Anti-oxidative content material used in drink and food manufacturing method |
| CN103735733A (en) * | 2013-12-30 | 2014-04-23 | 杭州海杭生物医药科技有限公司 | Compound preparation containing lutein ester and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 缓解视疲劳功能食品及其功效成分研究进展;金鑫等;《食品科学》;20151231;第36卷(第3期);第258-264页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105595341A (en) | 2016-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220118064A1 (en) | Multi-supplement compositions | |
| RU2572698C2 (en) | Probiotic bacteria having antioxidant activity and use thereof | |
| CN105595341B (en) | A kind of lycopene composition with anti-oxidant alleviation visual fatigue | |
| AU2017214669B2 (en) | Controlled-release and stratified cyclodextrin inclusion complex vehicles | |
| CN101330840A (en) | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision | |
| CN104839688A (en) | Eye care preparation and preparation method thereof | |
| US20220273570A1 (en) | Self-Microemulsifying Multi-Deliverable Systems | |
| CN103735616A (en) | Microencapsulated preparation for protecting eyesight and preparation method thereof | |
| CN108968069A (en) | Alleviate asthenopia, improves eyesight, is anti-oxidant, the composite soft capsule and preparation method of protection retina | |
| CN108902973A (en) | A kind of cowberry lutein particle and preparation method thereof | |
| KR20140017977A (en) | Vita hybrid tablet for senior and manufacturing method thereof | |
| WO2007120007A1 (en) | Extract of echinosophora koreensis removing hangover and having anti-oxidant activity | |
| US20220304927A1 (en) | Mitochondrial Performance Enhancement Nanoemulsion Method | |
| US20230398164A1 (en) | Intra-Oral Nanoemulsion Including Monolayer Surfactant Bound Particles for Balancing Histamine Response | |
| Carlan | Development of the microencapsulation of soluble vitamins with different biopolymers by a spray drying process, for medical, pharmaceutical and food applications | |
| US20220265748A1 (en) | Liver Activation Nanoemulsion, Solid Binding Composition, and Toxin Excretion Enhancement | |
| AU2008256690A1 (en) | Methods of making and using nano scale particles | |
| Jiménez | Microencapsulated bioactive components as a source of health | |
| CN106798734A (en) | A kind of soft capsule containing Co-Q10 and its preparation and application | |
| US20160317452A1 (en) | Methods of Making and Using Nano Scale Particles | |
| CN117562255A (en) | Composition for relieving visual fatigue and preparation method thereof | |
| CN109549172A (en) | A kind of functional food and preparation method thereof for alleviating visual fatigue | |
| Seshadri et al. | Bioavailability of Spirulina Carotenes in Preschool Children (Dec, 1990) | |
| CN106727660A (en) | Lift composition and its application of body immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Yingyan Inventor after: Xu Guohua Inventor after: Shi Hao Inventor after: Tian Zhibin Inventor after: Wang Wenfeng Inventor before: Shi Hao Inventor before: Xu Guohua Inventor before: Tian Zhibin Inventor before: Wang Wenfeng Inventor before: Wang Yingyan |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |